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Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the
protein phosphatase inhibitor okadaic acid involves the potentiation of
anti-mitotic effects and induction of apoptosis in human tumour cells
K-I Kawamura, D Grabowski, K Weizer, R Bukowski and R Ganapathi
Department ofCancer Biology, Research Insitute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195.
Summary Cellular insensitivity to vinca alkaloids is suggested to be primarily due to drug efflux by
P-glycoprotein (P-gp). The anti-epileptic phenytoin (DPH), which does not bind to P-gp, can selectively
enhance vincristine (VCR) cytotoxicity in wild-type (WT) or multidrug-resistant (MDR) cells. We now
demonstrate that the protein phosphatase inhibitor okadaic acid (OKA) can mimic the effect of DPH by
selectively enhancing cytotoxicity of vinblastine (VBL), but not taxol and doxorubicin, in human leukaemia
HL-60 cells. Both DPH and OKA potentiate the anti-mitotic effects of VBL by enhanced damage to the
mitotic spindle, resulting in prolonged growth arrest. Also, unlike VBL alone, in human leukaemia or
non-small-cell lung carcinoma cells treated with VBL plus DPH, recovery from damage to the mitotic spindle
is compromised in drug-free medium and cell death by apoptosis in interphase ensues. Since protein
phosphatases are involved with the regulation of metaphase to anaphase transit of cells during the mitotic
cycle, enhanced VBL cytotoxicity in the presence of DPH or OKA may involve effects during metaphase on
the mitotic spindle tubulin leading to growth arrest and apoptosis in interphase. These novel results suggest
that DPH or OKA could be powerful tools to study cellular effects of vinca alkaloids and possibly for the
development of novel therapeutic strategies.
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Tumour cell resistance to drugs that differ both in structure
and/or mechanism of action is suggested to be primarily due
to efflux of drug against a concentration gradient by the
membrane protein, P-glycoprotein (Endicott and Ling, 1989;
Gottesman and Pastan, 1993). Cellular insensitivity to the
clinically important anti-tumor vinca alkaloids vincristine
(VCR) or vinblastine (VBL) is attributed to overexpression of
P-glycoprotein (P-gp), and interfering with P-gp activity is a
strategy widely adopted for enhancing drug cytotoxicity
(Georges et al., 1990). We have previously reported that the
anti-epileptic phenytoin (DPH), which can affect microtubule
polymerisation selectively, enhances the cytotoxic effects of
VCR in wild-type (WT) or multidrug-resistant (MDR) cells
(Rall and Schleiffer, 1990; Ganapathi et al., 1993). A notable
characteristic of DPH is its ability to enhance VCR cytotox-
icity without binding to P-gp or enhancing drug accumula-
tion (Ganapathi et al., 1993). Also while the effects of DPH
were selective for VCR, concentrations of DPH that
enhanced cytotoxicity were markedly lower than those
reported to inhibit tubulin polymerisation (MacKinney et al.,
1978, 1980; Ganapathi et al., 1993).
The treatment of cells with the protein phosphatase
inhibitor okadaic acid (OKA) can produce an anti-mitotic
effect (Yamashita et al., 1990; Vandre and Wills, 1992).
Further, protein phosphatases have also been suggested to be
involved in mitotic exit as well as cytoskeletal integrity
(Eriksson et al., 1992; Fernande et al., 1992; Gurland and
Gundersen, 1993). Since the anti-mitotic effect of OKA or
DPH compared with that induced by VBL may involve
distinctly different mechanisms, we have investigated the cel-
lular effects induced by VBL in the presence of non-cytotoxic
concentrations of DPH or OKA in human tumour cells.
Our results demonstrate that OKA can mimic the effects of
DPH by selectively enhancing the cytotoxicity of VBL but
not doxorubicin or taxol. Furthermore, unlike VBL alone,
anti-mitotic effects from damage to the mitotic spindle as
well as cell death by apoptosis (Kerr et al., 1994; Smets,
1994) is pronounced following treatment with VBL plus
DPH or OKA.
Materials and methods
The human promyelocytic leukaemia HL-60 cells obtained
from the American Type Culture Collection, Rockville, MD,
USA were cultured in RPMI-1640 (M.A. Bioproducts,
Gaithersburg, MD, USA) supplemented with 2 mM L-
glutamine and 10% fetal bovine serum (M.A. Bioproducts).
Human non-small-cell lung carcinoma NSCLC-3 cells, estab-
lished in culture (Wells et al., 1994) from a surgical specimen
was maintained in RPMI-1640 supplemented with 2 mM L-
glutamine and 20% fetal bovine serum (FBS). Doubling time
in culture of the HL-60 and NSCLC-3 cells was 40 h and
50h respectively. The choice of these model systems was
based on the need to establish the modulating efficacy of
DPH with VBL in human tumours as well as tumours not
restricted to the haematopoietic system.
The effect of DPH or OKA on the mitotic block and
cytotoxicity induced by VBL was determined in HL-60 or
NSCLC-3 cells treated for 48 h with DPH or OKA alone and
in combination with VBL. Control and treated cells were
subsequently analysed for: (a) cytotoxicity; (b) mitotic arrest
and spindle damage by immunofluorescence using an a-
tubulin antibody; and (c) apoptosis based on
immunofluorescent detection of 3'-OH ends of DNA labelled
with fluorescein-12-dUTP or DNA fragmentation by agarose
gel electrophoresis.
In vitro cytotoxicity
Cytotoxicity was determined either by trypan blue dye ex-
clusion using a haemacytometer or in a soft-agar colony
assay. The soft-agar colony assay was carried out by plating
control or treated cells in RPMI-1640 supplemented with
2 mM L-glutamine, 20% FBS and 0.3% agar. Following
incubation for 10 days in a humidified 5% carbon dioxide
plus 95% air atmosphere, the colonies were counted using an
automated counter (Ganapathi et al., 1993). Colony forming
efficiency under these conditions for control untreated HL-60
and NSCLC-3 cells was 14% and 7% respectively.
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Analysis ofmitotic spindle morphology
Cytospin preparations of control and treated cells were
rapidly air dried and fixed for 20 min in 3.7% formaldehyde
in a buffer containing 0.1 M 1,4-piperasine diethanesulfonic
acid, pH 6.9, 1 mM magnesium sulphate and 2 mM ethyleneg-
lycol bis (P-aminoethyl) ethyl -N,N,N',N'-tetraacetic acid -
2 M glycerol. Fixed cells were washed in phosphate-buffered
saline (PBS), treated with 0.3% Nonidet P-40 in PBS, washed
and stained with mouse monoclonal antibody to a-tubulin
(Sigma, St Louis, MO, USA) for 30 min. Slides were air
dried and stained with FITC or TRITC conjugated goat
anti-mouse IgG F(ab')2 antibody for 30 min (Cappel, Dur-
ham, NC, USA) and mounted in 1 mg ml ' p-phenylene-
diamine in 70% glycerol/PBS. Slides were examined in an
Olympus BH2 microscope equipped with an epifluorescence
attachment using: (a) exciter filter IF490 + EY455 and bar-
rier filter Y455 for FITC; and (b) exciter filter IF-545 + BG-
36 and barrier filter R610 for TRITC. The procedure des-
cribed is an adaptation of that published by Leung et al.
(1992). A minimum of 1000 cells in three separate fields were
scored to determine the mitotic index. A minimum of 100
mitotic cells demonstrating multipolar spindle poles (>s 3)
were grouped to quantify abnormalities. Morphology of the
spindles were also examined for collapse of the spindle and
for heavily condensed and/or fragmented mitotic apparatus
(Vandre and Wills, 1992).
Detection ofapoptotic cells
Microscopic evaluation was carried out as described by Gav-
rieli et al. (1992). Briefly, cytospin preparations were labelled
using terminal transferase and fluorescein-12-dUTP (Boehr-
inger Mannheim, Indianapolis, Ins, USA). Slides were
examined in a fluorescence microscope as described earlier
and apoptotic cells scored by counting a minimum of 200
cells per field in three separate fields.
Agarose electrophoresis for internucleosomal fragmenta-
tion was carried out as described by Grant et al. (1992).
Briefly, control and treated cells (20 x 106) in lysis buffer
(5 mM Tris base, 20 mM EDTA, 0.5% Triton X-100,
pH 8.0 + 100 mg ml-' proteinase K) were incubated at 56°C
for 18 h and centrifuged at 30000g for 45 min at 4°C to
separate the low molecular weight fragments. The super-
natant was subsequently incubated at 37°C for 4 h in the
presence of 100fig ml-' RNAase A. The electrophoresis was
performed in 2% LMP agarose (BRL, Life Technologies,
Gaithersburg, MD, USA) in TAE buffer (40 mM Tris-acetate,
1 mM EDTA, pH 8.3) containing ethidium bromide. Samples
were loaded onto the gel after mixing with 15% Ficoll and a
100 bp DNA ladder was used as a marker. After overlay of
the gel with TAE buffer electrophoresis was carried out for
3 h at 65 V and the gel visualised under ultraviolet light.
Results and discussion
The data in Figure 1 demonstrate that DPH in a dose-
dependent fashion enhances the cytotoxic effect of VBL in
HL-60 or NSCLC-3 cells. While these observations extend
our earlier findings with VCR, an important distinction was
the requirement of simultaneous exposure to VBL plus DPH
for at least one cell generation cycle for maximal potentiation
of cytotoxicity. In order to determine a mechanistic basis
governing the cellular effects of DPH in enhancing VBL
cytotoxicity, HL-60 or NSCLC-3 cells were treated with VBL
and/or DPH for 2 days followed by recovery for an addi-
tional 4 days in drug-free medium. The experimental design
with HL-60 cells also involved high concentrations of VBL
alone, to rule out that effects of VBL + DPH were merely
related to altered drug levels and damage. The results in
Figure 2a indicate that while differences between VBL or
VBL + DPH were minimal during drug exposure, the
recovery of proliferation in drug-free medium of VBL-treated
cells was similar to the untreated control, in contrast to a
persistent abrogation of proliferation in cells treated with
VBL + DPH. The mitotic block induced (Figure 2b) between
VBL or VBL + DPH was similar at the end of treatment and
a rapid reversal to control values was apparent within 2 days
in drug-free medium. In contrast, while apoptosis in VBL-
treated cells during recovery in drug-free medium was similar
to the control, the apoptotic response was maximal and
persistent with VBL + DPH (Figure 2c). To characterise
whether these findings with VBL + DPH were unique to
leukaemic cells, the lung cancer NSCLC-3 model system was
also evaluated. The data in Figure 3a demonstrate that only
cells treated with VBL + DPH exhibit compromised recovery
of proliferation in drug-free medium. The mechanistic basis
for the compromised recovery of proliferation in drug-free
medium in cells treated with VBL + DPH is possibly due to
abnormal mitotic spindle (multipolar) morphology (Figure
3b) and the dominant persistence of an apoptotic response
(Figure 3c). Overall, either in leukaemic HL-60 or lung
cancer NSCLC-3 cells, the combination of VBL + DPH
results in persistent growth arrest and apoptosis even in
drug-free medium. Notably, within the range of VBL concen-
trations that can be achieved clinically with manageable tox-
icity (Rowinsky and Donehower, 1992), our data suggest that
VBL, unlike VBL + DPH, is cytostatic. Data on double
labelling (a-tubulin/fluorescein-12-dUTP) in Table I demon-
strate that in HL-60 cells following treatment with VBL-
+ DPH, apoptotic cells were about 3-fold higher than cells
arrested in mitosis. Since few if any cells were scored as
mitotic and apoptotic, mechanistically our data demonstrate
that the apoptosis induced by VBL + DPH is persistent even
in interphase.
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Figure 1 Effect of DPH on VBL cytotoxicity in HL-60 (a) and
NSCLC-3 (b) cells. Data are the mean value from at least dup-
licate experiments, s.d. < 15%. Survival of cells treated with
36.5jLM or 731lM DPH alone was 97-100%. _, 0 tLM DPH;
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inhibitor OKA on the mitotic index, induction of apoptosis
and cytotoxicity with VBL, using the human promyelocytic
leukaemia HL-60 cells. The modulating effect of OKA on
cytotoxicity was determined at the IC50 of doxorubicin
(DOX), VBL or taxol (TXL) alone, which was obtained from
dose-response curves. The data in Figure 4 indicate that a
concentration of 10 nM OKA, which by itself is marginally
cytotoxic (<5% cell kill), enhances the cytotoxic effects of
VBL > 3-fold. In contrast, enhancement of cell kill observed
with the combination of OKA and the mechanistically
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Figure 2 Proliferation (a), mitotic arrest (b) and apoptosis (c) in
HL-60 cells following treatment with DPH, VBL or VBL + DPH
for 2 days followed by recovery in drug-free medium for 4 days.
Treatment was initiated at starting density of 0.5 x 106 cells ml-'
and following treatment for 2 days samples were washed in
drug-free medium, recovered by centrifugation and resuspended
in fresh medium at a 0.3 x 106 trypan blue dye-excluding cells per
ml. Control and treated samples were analysed as described in
Materials and methods on days 2, 4 and 6.
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Figure 3 Proliferation (a), mitotic spindle pole number (b) and
apoptosis (c) in NSCLC-3 cells following treatment with DPH,
VBL or VBL + DPH for 2 days followed by recovery in drug-free
medium for 4 days. Control and treated samples were analysed as
described in Materials and methods on days 2, 4 and 6.
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different microtubule poison, taxol or the topoisomerase II
inhibitor doxorubicin is minimal. Statistical analysis of data
in Figure 4 using a series of t-tests adjusted for multiple
testing indicated that the combination of VBL + OKA was
significantly (P = 0.001) more effective than either VBL or
OKA alone. The results for TXL and DOX were less
definitive. While the pleiotropic cellular effects of OKA are
recognised, it is important to note that under the experiment-
al conditions, OKA selectively enhances the cytotoxicity of
VBL vs TXL or DOX, and the negative control compound,
1-nor-okadaone, which resembles OKA in physical properties
and chemical structure, does not enhance VBL cytotoxicity at
concentrations as high as 100 nM. The ability of OKA to
mimic DPH in the potentiation of anti-mitotic effects and
induction of apoptosis induced by VBL is also supported by
data in Figure 5, which demonstrate that unlike VBL alone,
the combination of VBL and OKA results in an increase of
> 3-fold and > 2-fold of mitotic and apoptotic cells respec-
tively.
Since cells demonstrating apoptosis based on labelling with
fluorescein-12-dUTP exhibited nuclear chromatin condensa-
tion and segregation, we also determined internucleosomal
DNA fragmentation by agarose gel electrophoresis. As
shown in Figure 6 the formation of a 200 bp DNA ladder
characteristic of apoptotic cell death is markedly enhanced
only with the combination of VBL + OKA (Figure 6a) and
VBL + DPH (Figure 6b).
Tumour cell insensitivity to VBL is generally accepted to
be due to drug efflux by P-gp (Endicott and Ling, 1990;
Gottesman and Pastan, 1993). We now demonstrate that the
Table I Analysis of apoptosis anid mitotic arrest in double labelled
(a-tubulin, fluorescein-12-dUTP) HL-60 cells
ApoIbotic indexv Mitotic in(lex
Treatment" (002h (0jh
Control 2.8 1.0 2.7 1.3
73fMm DPH 2.1 1.0 2.8±0.5
1.93 nM VBI 12.6 + 0.9 7.5 + 0.9
1.93 llM VBL + 73MM DPH 31.2 ± 3.8 10.2 + 2.3
HI -60 cells were treated as indicatcd for 48 h and cytospin
preparations stained with a-tubulin antibody and
fluorescein-12-dUTP. hSlides were examined in a fluorescence
microscope and a minimum of 200 cells per field in three separate
fields scored. Values are mean + standard deviation from a
representative experiment. Few if any cells were identitied to be in
mitotic arrest and apoptotic.
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Figure 5 Anti-mitotic and apoptotic response of HL-60 cells
treated with 2.75 nm vinblastine (VLB) in the absence or presence
of 10 nM okadaic acid (OKA). HL-60 cells were treated for 24 h
and mitotic (a) or apoptotic (b) cells scored after staining with
a-tubulin antibody or fluorescein-12-dUTP respectively.
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Figure 4 Modulation of vinblastine (VBL), taxol (TXL) and
doxorubicin (DOX) cytotoxicity by 10 nm okadaic acid (OKA) or
100 nmI l-nor-okadaone (NOD) in human leukaemia HL-60 cells
treated for 24 h with 2.75 nm VLB, 5 nM VLB, 5 nm TXL or
30 nM DOX. Concentrations of DOX, TXL or VBL producing
about 50% cell kill were derived from dose-response curves and
used to evaluate the effects of OKA or NOD on cytotoxicity. Cell
survival was measured by a soft-agar colony assay. Range of
values between replicate experiments was between 10% and 15%.
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Figure 6 Agarose gel electrophoresis of DNA extracted from
human promyelocytic leukaemia, HL-60 cells (a) or NSCLC-3
cells (b). HL-60 cells were treated for 24h with: lane 1, 100bp
DNA ladder; lane 2, control; lane 3, 10 nM. OKA; lane 4,
2.75 nm vinblastine; and lane 5, 2.75 nm vinblastine plus 10 nM
OKA. NSCLC-3 cells were treated for 48 h with: lane 1, control:
lane 2, 73 IM DPH, lane 3, 1.93 nm VBL; lane 4, 1.93 nM
VBL + 73 LM DPH; and lane 5, marker 100 bp DNA ladder.
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anti-epileptic DPH (Rall and Schleifer, 1990) or the protein
phosphatase inhibitor OKA (Vandre and Wills, 1992) can
selectively enhance VBL cytotoxicity in human leukaemic
(HL-60) or NSCLC-3 cells due to sustained growth arrest,
damage to the mitotic spindle and induction of apoptosis.
Both DPH or OKA can inhibit cell-cycle traverse in the
mitotic cycle, leading to arrest in metaphase (MacKinney,
1980; Vandre and Wills, 1992). Metaphase arrest induced by
DPH is suggested to involve effects on polymerisation of
tubulin (MacKinney, 1978), while with OKA, inhibition of
phosphatases involved in the mitotic cycle has been reported
(Yamashita et al., 1990; Vandre and Wills, 1992). Since
concentrations of DPH that are capable of inducing
measureable effects on polymerisation-depolymerisation
kinetics of purified tubulin or metaphase arrest of treated
cells are in excess of 300gtm (MacKinney, 1978), it is possible
that alternate mechanisms are involved in the modulation of
VBL cytotoxicity. Growth arrest by OKA in metaphase
(Yamashita et al., 1990; Vandre and Wills, 1992) is suggested
to involve inhibition of dephosphorylation events regulating
metaphase to anaphase transit (Yamashita et al., 1990; Fer-
nande et al., 1992; Vandre and Wills, 1992). Other effects of
OKA during the mitotic cycle include activation and inac-
tivation of p349 kinase and possible suppression of the
cyclin proteolysis pathway (Yamashita et al., 1990). There is
no direct evidence demonstrating effects of OKA on tubulin,
but inhibitors of protein phosphatases such as OKA and
calyculin A affect regulation of microtubule stability by the
selective breakdown of stable microtubules in fibroblasts or
epithelial-like cells (Gurland and Gunderson, 1993).
The induction of apoptosis in OKA (>30 nM)-treated cells
has been reported (Zheng et al., 1994). While induction of
apoptosis by DPH has not been reported, we have observed
apoptosis only in cells treated with >300gM DPH (data not
shown). The results in Figures 2, 3, 5 and 6 demonstrate that
73 gM DPH or 10 nM OKA alone has a minimal effect on
apoptosis, but in combination with VBL pronounced and
persistent apoptosis is observed. Notably, enhanced cytotox-
icity with VBL plus DPH or OKA may be related to apop-
totis during interphase, since cells labelled with fluorescein-
12-dUTP and identified as apoptotic were not arrested in
mitosis. Also, while growth arrest of VBL-treated cells is
apparent only during treatment, cells treated with VBL plus
DPH or OKA exhibit continued growth arrest in drug-free
medium. Thus the potentiation of VBL cytotoxicity by DPH
or OKA is due to prolonged inhibition of proliferation and
consequent apoptosis. Apoptosis in response to cellular
damage is dependent on the expression of WT p53 (Oren,
1994). The pronounced apoptosis observed in this study with
HL-60 or NSCLC-3 cells treated with VBL + DPH is thus of
interest since: (a) HL-60 cells do not express p53 due to
extensive deletion ofthe gene (Wolfand Rotter, 1985; Collins
1987); and (b) NSCLC-3 cells are hemizygous for p53 expres-
sion based on the absence of a WT allele and expression of
mutant p53 with a tyrosine-*cysteine mutation at amino
acid 163 (R Ganapathi et al., manuscript in preparation).
Ongoing studies demonstrate that the modulating effects of
DPH or OKA on VBL cytotoxicity is also observed in HL-60
or NSCLC-3 cells with the MDR phenotype (R Ganapathi et
al., manuscript in preparation). Since neither DPH or OKA
bind to P-gp (Chambers et al., 1993; Ganapathi et al., 1993)
the differential effects of OKA or DPH on MDR-associated
drugs (VBL vs TXL or DOX) is novel, since increasing drug
accumulation by interfering with P-gp function is the strategy
for enhancing drug cytotoxicity (Georges et al., 1990). The
potential therapeutic benefit with the combination of DPH
and VBL in a clinical setting is currently under investigation
in a phase I setting, and preliminary results suggest that
DPH (400mg day-') can be safely administered in combina-
tion with 2.25 mg VBL m2 day-' as a continuous infusion
for 5 days (Peereboom et al., 1995).
Overall, our results demonstrate that the protein phos-
phatase inhibitor OKA can mimic the cellular effects of DPH
in selectively enhancing the cytotoxicity of VBL. Since under
the experimental conditions evaluated VBL is cytotstatic vs
VBL plus DPH or OKA cytocidal, interfering with
metaphase transit, damage to the mitotic spindle and apop-
tosis during interphase are mechanistically involved in the
potentiation of VBL cytotoxicity. These novel results suggest
the use of DPH or OKA as a powerful tool to study cellular
effects ofvinca alkaloids and possibly for the development of
novel therapeutic strategies.
Abb
VCR, vincristine; VBL, vinblastine; DPH. phenytoin; OKA. okadaic
acid, DOX. doxorubicin; TXL, taxol; FBS, fetal bovine serum. P-gp.
P-glycoprotein; PBS, phosphate-buffered saline.
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